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Abstract 
Due to kidney or liver failure, normally harmless doses of prescription drugs can have 
toxic effects leading to further medical complications (Ing, 1979). Those suffering from kidney 
and liver failure frequently suffer related and unrelated ailments, but are restricted on the 
medications and the amounts thereof. Site--‐specific ailments such as arthritis, localized viral 
infections, neuropathic pain, and other illnesses could be treated with smaller doses if the 
treating drug were only made available at the targeted site. 
The project goal is to develop a drug delivery system using human serum albumin 
(HSA) as a carrier for anti--‐inflammatory, antibiotic, antiviral, and antioxidant drugs. This drug 
delivery system is unique in using rapid--‐sequence, local hyperthermia, hypothermia, and 
ultrasound at a specific site of interest in the body. The proposed system is designed for 
patients with compromised liver and kidney function who are unable to safely use normal, oral 
doses of these medication types. 
 
Significance and Innovation 
The proposed drug delivery system is pertinent to the study of drug delivery strategies 
for patients with compromised kidney and liver function. Studies have shown that non--‐steroidal 
anti--‐inflammatory (NSAID) drugs, such as ibuprofen, have a broad spectrum of adverse side 
effects on kidney and liver function (Bushra, 2010). According to Bessone, the use of such 
NSAID drugs could potentially cause transient, severe or sudden hepatic failure  (Bessone, 
2010). It can then be concluded that the use of such drugs requires constant monitoring of their 
effects especially on compromised livers and kidneys during the course of treatment. A 
localized drug delivery method could potentially be a safer alternative as it allows for the 
administration of drug without exposing the entire body to the same dose (Ibsen, 2012). 
Using  human  serum  albumin  (HSA)  as  a  drug  carrier  allows  a  more  localized  drug 
delivery to the  tissues  of  interest.  In  addition,  this  drug  delivery  system  can  reduce  the  dosage 
of drug required as well as the severity of side effects. A programmed  device  will  control  the 
release of drug through localized  change  of  temperature  and  ultrasound  application.  The 
localized change of temperature will  induce  the  denaturation  and  renaturation  mechanisms  of 
the HSA, which will release the drug. In this study, ibuprofen is used as a proof of  concept, 
however, this drug delivery system is designed to work with various types of drugs, such as anti--‐ 
inflammatory,  antibiotic,  antiviral   and   antioxidant   drugs.   Finally,   the   success   of   this   drug 
delivery  system  will  be  evaluated  using  in  vitro  tissue   testing.   Various   methods   such   as   PCR 
array will be used to determine the effectiveness of the treated HSA on fibroblast  cells  with 
induced     inflammation. 
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Specific Aims 
 
1. Identify a binding method for preparation of ibuprofen--‐HSA compound: 
1) Perform viable binding methods 
2) Verify drug binding to the human serum albumin 
3) Select the best candidate based on decision matrices 
2. Select method of drug release: 
1) Use testing and instrumentation to find optimal heat, cooling, and ultrasound 
parameters for drug release in phosphate buffer solution 
3. Develop a programmable device to provide localized hyperthermia, hypothermia, and 
ultrasound for drug release from albumin proteins: 
1) Following optimization testing in the second aim, an extracorporeal device will 
be constructed using microcontrollers to orchestrate sequential steps in the 
conformation change of the HSA and release of the ibuprofen 
4. In--‐vitro testing of drug release with live tissue cultures: 
1) Fibroblast cells will be cultured and exposed to an inflammatory inducing agent, 
followed by the released and unreleased HSA--‐drug compound 
2) Assays will be used to test the expression of inflammation--‐related factors by the 
cells 
Approach and Methods 
Specific Aim 1 (Binding Method) 
Human serum albumin is known for its ability to bind a wide variety of compounds, such 
as different fatty acids and ibuprofen(Galantini, 2010). HSA is also known to contain a single 
fluorescent tryptophan near the primary binding site which will be employed for the binding 
verification using shifts in fluorescence (Thumser, 1998). 
HSA will be dissolved in a 10mM phosphate buffer solution. The solution will be stirred 
for 12 hours and then filtered. Ibuprofen will also be dissolved in a phosphate buffer and will be 
added to the HSA solution to be bound at a stoichiometric ratio of 10:1 drug to HSA (Galantini, 
2010). 
Fluorescence and dynamic light scattering (DLS) techniques will be used to verify drug 
binding. Fluorescence will be measured using an excitation wavelength of 295 nm with 
emission at 330 nm and 350 nm. It is expected that fluorescence will decrease when the drug is 
bound to the protein (Thumser, 1998). The instruments for verification and the glassware have 
already been purchased. The human serum albumin and the ibuprofen are the primary source 
of lab costs for this section of the project. 
 
Specific Aim 2 (Release Method) 
Human serum albumin is a protein composed entirely of alpha helices. Upon heating to 
75 degrees C followed by immediate cooling, beta structures begin to form (Wetzel, 1980). This 
change in protein conformation is likely to affect the hydrogen bond between the drug and the 
protein. Ultrasound is proposed to add energy as a final step in localized drug release from HSA. 
This release method will be tested for success and to verify the drug is still functional after 
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treatment. 
A mixture of the HSA--‐drug compound will be prepared in a 10 mM phosphate buffer 
solution. The mixture will be externally heated at a temperature of 80 degrees C (the highest 
safe temperature for the surface of the body) followed by external cooling at 0 degrees C 
(Wetzel, 1980). The solution will then be exposed to ultrasound waves. Drug release will be 
verified by measuring the fluorescence of the HSA, which should change as the drug is released 
(Thumser, 1998). 
 
Specific Aim 3 (Device Design) 
A device attached to the surface of the skin will be devised to cause the optimal 
temperature fluctuation and ultrasound interaction needed to release the drug from the HSA. 
Microcontroller technology will be used to operate the three main components of the device. 
First, a heating element will be used to raise the tissue temperature. A cooling jacket with 
circulating water will be used to then reduce the temperature and induce beta sheet 
proliferation. Ultrasound will applied last to instil more energy to the molecules, promote drug 
release, and serve as an additional form of pain relief. 
In later stages of development, a depiction of the final product will be drafted using 
specified drafting software, such as AutoCad or SolidWorks. It is expected that a prototype will 
be built, tested and used for demonstration. Figure 1 shows the components of the device 
design process. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The overarching goal of the proposed research is the development of a drug delivery 
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system using a device at the skin surface to cause drug release from human serum albumin. 
 
Specific Aim 4 (Tissue Testing) 
In vitro tissue testing using cultured fibroblast cells will be used as a final means to 
evaluate the success of the drug delivery system. Fibroblast cell culture will be stimulated using 
inflammatory cytokine or hypoxic culture conditioning in order to stimulate an inflammatory 
response (Pooley, 2013). The HSA--‐ibuprofen compound will then be treated with changes in 
temperature and ultrasound outlined previously to release the drug. The HSA--‐ibuprofen 
compound will then be applied to the inflamed fibroblast cell culture. 
Polymerase chain reaction (PCR) array and assay--‐specific components will be used for 
the quantitative detection of biomarkers and proteins  indicating  inflammation  present  before 
and after the cells are treated with HSA--‐drug compound. In addition, cell population growth will 
be measured on a daily basis to further support the effects of the HSA drug delivery system in 
treating inflammation as well as to ensure that the HSA does not change the properties of the 
ibuprofen. A comparison will be made between the cell culture that is treated with the HSA--‐ 
ibuprofen mixture and the cell culture that is used as a control. 
 
Communication of Results 
Findings from research will be presented in the annual review of senior projects to the 
faculty and students of the Department of Biological Engineering at Utah State University. Any 
significant findings may be submitted for publishing with a journal with consideration for 
patenting developed novel technologies. 
 
Project information will be organized into a podium presentation for submission for the 
American Chemical Society Northwest Annual Meeting in Montana during late June of 2014, 
and the Biomedical Engineering Society (BMES) Annual Meeting in late October of 2014. 
Information from this study may also be presented at local student showcases. 
 
Description of Personnel 
● Sara: responsible for device design using a microcontroller. She has experience with 
microcontroller code and medical device design. She also has experience in statistical 
analysis. 
● Sean: responsible for the analysis and optimization of drug binding and targeted release 
from HSA. He has experience with useful instrumentation (DLS, fluorometer, mass spec, 
LC--‐MS/MS, ion chromatography, nuclear magnetic resonance, etc.). 
● Stephanie: responsible for tissue testing of drug release. She has experiences in tissue 
culture techniques such as performing cell passages, enzyme--‐linked immunosorbent 
assay (ELISA), immunohistochemistry and data analysis. 
● Dr. Elizabeth Vargis: the mentor of this project. She has extensive research experience in 
cell cultures such as analyzing microfluidic platform with micropatterned surfaces in 
retinal cells. In addition, she has experienceusing Raman spectroscopy (SERS) to detect 
biomarkers found in cells. 
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Timeline 
 
February 15, 2014:  Submit URCO Grant Proposals 
March 1, 2014:  Begin drug binding / release testing 
March 15, 2014: Conclude verification of drug binding / release method 
March 16, 2014:  Start device design and production 
April 22, 2014:  Interim Report to Senior Design Project Coordinator 
May 1, 2014:  Complete device design and production 
May 5, 2014:  Tissue testing using fibroblast cells 
June 1, 2014: Completion of tissue testing 
June  22--‐25,  2014:  American  Chemical  Society  (ACS)  Northwest  Annual  Meeting 
October  22--‐25,  2014:  Biomedical  Engineering  Society  (BMES)  Annual  Meeting 
December  8--‐12,  2014:  Presentation  of  final  project  at  the  senior  design  review 
Spring 2015: Abstracts will be submitted for UCUR, Research on Capitol Hill, and the USU 
Student Showcase 
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Budget 
 
Total Amount Requested: $1300 
URCO Grant: $650 
BE Department Funding: $650 
 
URCO BUDGET SUMMARY 
  
EXPENSES: AMOUNT: PURCHASED BY: 
MATERIAL/SUPPLIES:   
Albumin Protein (500 mg) $79.00 BE Department 
S--‐Ibuprofen (1000 mg) $41.30 BE Department 
Ibuprofen Sodium Salt (100 g) $44.80 BE Department 
Trypan Blue Dye (100 mL) $14.90 BE Department 
Fibroblast Cell Line $270.00 BE Department 
Cell Media $22.00 BE Department 
Well Plates (50 plates) $118.00 BE Department 
Biomarker Detection Assay $540.00 URCO Grant 
MATERIALS SUBTOTAL $1130.00  
   
EQUIPMENT:   
Portable Ultrasound $110.00 URCO Grant 
Arduino & Electrical Components $60.00 BE Department 
EQUIPMENT SUBTOTAL $170.00  
BE DEPARTMENT TOTAL: $650.00  
URCO GRANT TOTAL: $650.00  
TOTAL: $1300.00  
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